Frontier Biotechnologies

Frontier Biotechnologies EBITDA per Employee

The EBITDA per Employee of Frontier Biotechnologies (688221.SS) as of Oct 24, 2026 is -486,912.95 CNY. In the previous year, EBITDA per Employee was -433,732.36 CNY — a change of 12.26% (lower).

EBITDA per Employee

-486,912.95CNY

YoY

12.26%

Last updated:

EBITDA per Employee of Frontier Biotechnologies is 2025 -486,912.95 CNY. EBITDA per Employee of Frontier Biotechnologies was 2024 -433,732.36 CNY. It decreases by 12.26% lower compared to the previous year.

The Frontier Biotechnologies EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-497,070.71 CNY
Jan 1, 2019
-328,196.97 CNY
Jan 1, 2020
-440,637.07 CNY
Jan 1, 2021
-593,115.82 CNY
Jan 1, 2022
-707,216.20 CNY
Jan 1, 2023
-623,693.47 CNY
Jan 1, 2024
-433,732.36 CNY
Jan 1, 2025
-486,912.95 CNY
The Frontier Biotechnologies EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-486,912.95CNY+12.26%
-433,732.36CNY-30.46%
-623,693.47CNY-11.81%
-707,216.20CNY+19.24%
-593,115.82CNY+34.60%
-440,637.07CNY+34.26%
-328,196.97CNY-33.97%
-497,070.71CNY+262.85%
-136,989.90CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Frontier Biotechnologies Stock analysis

What does Frontier Biotechnologies do? Frontier Biotechnologies, Inc. develops and sells medicines through its product portfolio, including Aikening and the Combination regiment of Albuvirtide (ABT) + 3BNC117, which is in clinical stage for HIV treatment. The company also offers transdermal analgesic patch AB001 for muscle, skeleton, and joint pain, currently in clinical development. Frontier Biotechnologies operates within the China market and serves overseas markets with its pharmaceutical products. The company generates revenue primarily from the research, development, and sale of its clinical-stage medicines, targeting both domestic and international healthcare providers and distributors. Its products are positioned for treatment of HIV and pain management, with AB001 focusing on non-invasive pain relief solutions. Frontier Biotechnologies focuses on advancing its pipeline through clinical trials to bring these therapies to market. Frontier Biotechnologies, Inc. is a biotechnology firm headquartered in Nanjing, Jiangsu, with 495 full-time employees. It conducts its business activities in China and overseas, leveraging its R&D capabilities to develop innovative treatments for unmet medical needs. The firm's revenue streams are derived from the commercialization of its pipeline products once they reach the market. Frontier Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Frontier Biotechnologies stock

EBITDA per Employee of Frontier Biotechnologies is -486,912.95 CNY in 2025.

EBITDA per Employee of Frontier Biotechnologies changed from -433,732.36 CNY to -486,912.95 CNY, representing a 12.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Frontier Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Frontier Biotechnologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Frontier Biotechnologies

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Frontier Biotechnologies